Viridian Therapeutics Stock Alpha and Beta Analysis
| VRDN Stock | USD 32.60 0.80 2.52% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Viridian Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Viridian Therapeutics over a specified time horizon. Remember, high Viridian Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Viridian Therapeutics' market risk premium analysis include:
Beta 0.94 | Alpha 0.71 | Risk 3.37 | Sharpe Ratio 0.25 | Expected Return 0.85 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Viridian Therapeutics Backtesting, Viridian Therapeutics Valuation, Viridian Therapeutics Correlation, Viridian Therapeutics Hype Analysis, Viridian Therapeutics Volatility, Viridian Therapeutics History and analyze Viridian Therapeutics Performance. Viridian Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Viridian Therapeutics market risk premium is the additional return an investor will receive from holding Viridian Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Viridian Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Viridian Therapeutics' performance over market.| α | 0.71 | β | 0.94 |
Viridian Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Viridian Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Viridian Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Viridian Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Viridian Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Viridian Therapeutics shares will generate the highest return on investment. By understating and applying Viridian Therapeutics stock market price indicators, traders can identify Viridian Therapeutics position entry and exit signals to maximize returns.
Viridian Therapeutics Return and Market Media
The median price of Viridian Therapeutics for the period between Thu, Sep 11, 2025 and Wed, Dec 10, 2025 is 23.01 with a coefficient of variation of 18.82. The daily time series for the period is distributed with a sample standard deviation of 4.62, arithmetic mean of 24.55, and mean deviation of 4.09. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | How Viridian Therapeutics Inc. stock reacts to bond yields - 2025 Year in Review Technical Confirmation Trade Alerts - newser.com | 09/30/2025 |
2 | Is Viridian Therapeutics Inc. stock attractive for growth ETFs - July 2025 Price Swings High Return Trade Guides - newser.com | 10/27/2025 |
3 | Viridian Therapeutics Releases Quarterly Earnings Results, Beats Estimates By 0.48 EPS | 11/06/2025 |
4 | Viridian Therapeutics Price Target Raised to 45.00 at Royal Bank Of Canada | 11/07/2025 |
5 | Wall Street Zen Upgrades Viridian Therapeutics to Hold | 11/10/2025 |
6 | Viridian Therapeutics Hits New 52-Week High Should You Buy | 11/14/2025 |
7 | RBC Capital Remains Bullish on Viridian Therapeutics Following Q3 2025 Results | 11/17/2025 |
8 | Viridian Therapeutics Revisiting Valuation After Analyst Upgrades and Robust Revenue Growth | 11/28/2025 |
9 | Will William Blairs Outperform Initiation Shift Viridian Therapeutics Narrative Among Institutional Investors | 12/04/2025 |
10 | With Viridian Therapeutics Stock Surging, Have You Considered The Downside - Trefis | 12/08/2025 |
About Viridian Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Viridian or other stocks. Alpha measures the amount that position in Viridian Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Dividend Yield | 8.52E-4 | 0.001448 | Price To Sales Ratio | 4.3K | 4.5K |
Viridian Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Viridian Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Viridian Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Viridian Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Viridian Therapeutics. Please utilize our Beneish M Score to check the likelihood of Viridian Therapeutics' management manipulating its earnings.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Viridian Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Viridian Therapeutics Backtesting, Viridian Therapeutics Valuation, Viridian Therapeutics Correlation, Viridian Therapeutics Hype Analysis, Viridian Therapeutics Volatility, Viridian Therapeutics History and analyze Viridian Therapeutics Performance. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Viridian Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.